The day's most important news and information. A Fourth Estate® Service

Saturday, April 17, 2021

BioNTech Will Price Vaccine Below Market Rates

BioNTech is planning to price the two-shot regimen of the COVID-19 vaccine below “typical market rates” and would even differentiate pricing between regions or nations. The company is currently first in the race to disclose interim information from a large-scale trial showing a highly effective COVID-19 vaccine.

BioNTech is planning to price the two-shot regimen of the COVID-19 vaccine below “typical market rates” and would even differentiate pricing between regions or nations. 

The company is currently first in the race to disclose interim information from a large-scale trial showing a highly effective COVID-19 vaccine.

During a Financial Times online event on Tuesday afternoon, the German biotech firm’s strategy chief Ryan Richardson explained that the price tag of the vaccine, which is co-developed with Pfizer and which has yet to win regulatory approval, will reflect the economic risks that its private-sector investors have incurred.

“We’ve tried to pursue a balanced approach that recognizes that innovation requires capital and investment so we plan to price our vaccine well below typical market rates reflecting the situation that we’re in and with the goal to ensure broad-based access around the world,” Richardson said at the event.

“I expect there to be differential pricing in certain regions of the world,” he pointed out, declining to elaborate on the different price tags.

Article © 2021 Fourth Estate® — All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

Recent Articles

spot_img

Get the Daily NewsBrief in your inbox

Related Stories